Glaucoma Trial, Recruiting (NCT06953349)

Glaucoma Trial, Recruiting NCT06953349 Sponsor: Barnet Dulaney Perkins Eye Centers Condition: Glaucoma

Printed from Voxsanity (voxsanity.com.au) — NCT06953349 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Glaucoma

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have glaucoma and have previously had one of the following eye procedures: CEIOL, OMNI, or Hydrus implant — with the device chosen because they were using more than one glaucoma eye drop before surgery
People who have at least 3 years of follow-up records from that procedure

Who may not be able to join:

People whose glaucoma is caused by a closed drainage angle, abnormal blood vessel growth in the eye, eye inflammation (uveitis), a condition present from birth, or other birth-related eye abnormalities
People who have had persistent swelling at the back of the eye (a condition called CME) that lasted 3 months or more after their surgery
People whose medical records are incomplete — for example, missing eye pressure measurements, medication history, or visual field test results from after their surgery
People who have previously had incisional eye surgery or another minimally invasive glaucoma procedure (MIGS) prior to the procedure being studied (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 22 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Christine Funke, Medical Doctor, Barnet Dulaney Perkins Eye Centers

Phone: 4804201005

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06953349

Sponsor: Barnet Dulaney Perkins Eye Centers

Phase: Not Applicable

Status: Recruiting

Condition: Glaucoma

Trial contact: 4804201005

More information: https://clinicaltrials.gov/study/NCT06953349

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have glaucoma and have previously had one of the following eye procedures: CEIOL, OMNI, or Hydrus implant — with the device chosen because they were using more than one glaucoma eye drop before surgery
People who have at least 3 years of follow-up records from that procedure

Who may not be able to join:

People whose glaucoma is caused by a closed drainage angle, abnormal blood vessel growth in the eye, eye inflammation (uveitis), a condition present from birth, or other birth-related eye abnormalities
People who have had persistent swelling at the back of the eye (a condition called CME) that lasted 3 months or more after their surgery
People whose medical records are incomplete — for example, missing eye pressure measurements, medication history, or visual field test results from after their surgery
People who have previously had incisional eye surgery or another minimally invasive glaucoma procedure (MIGS) prior to the procedure being studied (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 22 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Barnet Dulaney Perkins Eye Centers

Registry

ClinicalTrials.gov

Start date

31 March 2025

Est. completion

30 November 2025

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Measured Efficacy of Surgical Process with Phacoemulsification

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov